Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Zonisamide

FDA-approved product (capsule, oral), marketed as Zonegran, Zonisade, Zonisamide.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Zonisamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Epilepsy
  • Focal-onset seizure
  • Partial epilepsy
  • Seizure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiepileptics
FDA pharmacologic class
Anti-epileptic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli12.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae7.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis82.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 1 of 1 lab record
Open Zonisamide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Zonisamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT

    NCT00068770 · start 2003-10

    Registered record
    Registry ID
    NCT00068770
    Conditions
    Brain and Central Nervous System Tumors
    Interventions
    radiation therapy; Celecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2003-10
    Completion
    2006-05
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors
    Interventionradiation therapy; Celecoxib
    PhasePhase 2
    Registry statusTerminated

  • Zonisamide in the Treatment of Essential Tremor

    NCT00616343 · start 2003-06

    Registered record
    Registry ID
    NCT00616343
    Conditions
    Essential Tremor
    Interventions
    Zonisamide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2003-06
    Completion
    2012-12
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Tremor
    InterventionZonisamide
    PhaseNot applicable
    Registry statusTerminated

  • Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation

    NCT00298818 · start 2002-08

    Registered record
    Registry ID
    NCT00298818
    Conditions
    Epilepsy; Mental Retardation; Developmental Disabilities
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2002-08
    Completion
    2008-03
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy; Mental Retardation; Developmental Disabilities
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache

    NCT00055484 · start 2002-03

    Registered record
    Registry ID
    NCT00055484
    Conditions
    Migraine Headache
    Interventions
    zonisamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-03
    Completion
    2003-05
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headache
    Interventionzonisamide
    PhasePhase 2
    Registry statusCompleted

  • Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

    NCT00056576 · start 2002-02

    Registered record
    Registry ID
    NCT00056576
    Conditions
    Epilepsy, Complex Partial
    Interventions
    Zonisamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-02
    Completion
    2004-10
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy, Complex Partial
    InterventionZonisamide
    PhasePhase 3
    Registry statusCompleted